In Case You Missed It: News Roundup for Omnipod® 5 Automated Insulin Delivery (AID) System

Guest Blogger
Category: Science and Technology

At Insulet Corporation, makers of Omnipod®, we were born of innovation and a thirst for finding a better, simpler way. Our goal has been and continues to be to reduce burden and improve outcomes for people with diabetes.

Now, after several years in development, the Omnipod® 5 Automated Insulin Delivery (AID) System has officially been cleared by the Food and Drug Administration (FDA) for individuals ages 6 years and older with type 1 diabetes!

Omnipod 5 is the first tubeless AID system managed through a compatible smartphone1 in the U.S. and the only tubeless AID system that integrates with the Dexcom G6® Continuous Glucose Monitor (CGM) System2 to automatically adjust insulin delivery and manage glucose levels both day and night, helping to protect against highs and lows3. Like Omnipod DASH® it continues to be wearable and waterproof†.

But there’s so much more to know. Check out the press clippings below to learn more about the pivotal trial data, to watch a live interview with our President and CEO Shacey Petrovic and to hear from our Senior Vice President and Medical Director Dr. Trang Ly.

Juicebox // watch listen

Podcast host Scott Benner has an exclusive interview with President and CEO Shacey Petrovic and Medical Director Dr. Trang Ly to talk in-depth about the Omnipod 5 Automated Insulin Delivery (AID) System.

Nerdabetic // watch

Vlogger Kamil Armacki interviews President and CEO Shacey Petrovic about our founding story, features of Omnipod DASH and the future with the Omnipod 5 Automated Insulin Delivery (AID) System.

Diabetes Connections with Stacey Simms // listen

Podcast host Stacey Simms interviews Senior Vice President & Medical Director Dr. Trang Ly about the features of the Omnipod 5 Automated Insulin Delivery (AID) System and what makes it different from the other hybrid closed loop systems that are already on the market.

AJMC, The American Journal of Managed Care // read

AJMC highlights the pivotal study results and shares an expert Q&A on the Omnipod 5 Automated Insulin Delivery (AID) System with Dr. Amy B. Criego, MD, MS, and Dr. Bruce W. Bode, MD.

Healthline // read

Healthline shares the features of the Omnipod 5 Automated Insulin Delivery (AID) System, reviews the pivotal trial data and talks about its anticipated release.

Business Wire // read

BusinessWire gets into specifics of the Omnipod 5 Automated Insulin Delivery (AID) System pivotal study extension data and how it has shown significant improvements in glycemic control with one year of use.

Beyond Type 1 // read

Beyond Type 1 shares a summary of the highlights from the Omnipod 5 Automated Insulin Delivery (AID) System pivotal trial data published by the American Diabetes Association (ADA) Diabetes Care journal.

diatribe // read

diatribe reviews the Omnipod® 5 Automated Insulin Delivery (AID) System clinical trial results, calling them impressive following the European Association for the Study of Diabetes (EASD) 2021 conference.

__________

Don’t wait to experience Pod therapy. Get started on Omnipod DASH® today with a 30-day free trial*.

1For a list of compatible smartphone devices visit omnipod.com/compatibility
2Dexcom G6 is not included.
3Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Median time <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P=0.8153, respectively. Results measured by CGM.
†The Pod has a waterproof IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller and DASH PDM are not waterproof.
*To be eligible for 30 Days of Freedom Trial Program, you must complete and sign Program Enrollment and Personal Information Forms and may be required to submit additional documentation. Patients must have been prescribed Omnipod DASH for an FDA-approved indication. For new Pod Therapy patients coming from multiple daily injections or tubed pumps only. Free Omnipod DASH trial program is not available to beneficiaries of Medicare, Medicaid or other federal health care programs, or to members of certain commercial health plans. You agree not to sell, trade, return for credit or seek insurance reimbursement for the PDM or free Pods. After the 30-day trial, your out-of-pocket cost for Pods will depend on your insurance coverage. Other restrictions may apply. Cancel at any time. 30 Days of Freedom Trial Program terms and conditions are subject to change.